Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall surviv...
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
About this item
Full title
Author / Creator
Motzer, Robert J, Dr , Escudier, Bernard, MD , Tomczak, Piotr, MD , Hutson, Thomas E, DO , Michaelson, M Dror, MD , Negrier, Sylvie, Prof , Oudard, Stephane, Prof , Gore, Martin E, Prof , Tarazi, Jamal, MD , Hariharan, Subramanian, MD , Chen, Connie, PharmD , Rosbrook, Brad, MS , Kim, Sinil, MD and Rini, Brian I, MD
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Summary Background In a phase 3 trial comparing the efficacy and safety of axitinib versus sorafenib as second-line treatment for metastatic renal cell carcinoma, patients given axitinib had a longer progression-free survival (PFS). Here, we report overall survival and updated efficacy, quality of life, and safety results. Methods Eligible patients...
Alternative Titles
Full title
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1751229503
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1751229503
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(13)70093-7
